Logos Global Management LP Athira Pharma, Inc. Transaction History

Logos Global Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $1.36 Million - $6.68 Million	-497,285 Reduced 69.33%	220,000 $671,000
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $8.18 Million - $12.3 Million	-913,459 Reduced 56.01%	717,285 $9.68 Million
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $2.06 Million - $3.69 Million	-225,068 Reduced 12.13%	1,630,744 $21.2 Million
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $4.07 Million - $4.94 Million	445,000 Added 31.54%	1,855,812 $17.4 Million
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $4.1 Million - $8.35 Million	400,000 Added 39.57%	1,410,812 $14.4 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $1.06 Million - $1.87 Million	62,939 Added 6.64%	1,010,812 $18.6 Million
Q4 2020 Feb 16, 2021	SELL	$16.48 - $34.3 $1.2 Million - $2.5 Million	-72,939 Reduced 7.15%	947,873 $32.5 Million
Q3 2020 Nov 17, 2020	BUY	$16.02 - $18.46 $6.58 Million - $7.58 Million	410,812 Added 67.35%	1,020,812 $18.8 Million
Q3 2020 Nov 16, 2020	BUY	$16.02 - $18.46 $9.77 Million - $11.3 Million	610,000 New	610,000 $11.3 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $23.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.